[ET Net News Agency, 13 January 2022] HUTCHMED (China) Limited (00013) said the Center
for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted
Breakthrough Therapy Designation (BTD) to HMPL-523, a novel, investigational spleen
tyrosine kinase (Syk) inhibitor, for the treatment of chronic adult primary immune
thrombocytopenia patients who have received at least one prior therapy.
HMPL-523 is a novel, investigational, selective small molecule inhibitor for oral
administration targeting spleen tyrosine kinase, also known as Syk. Syk is a major
component in B-cell receptor signalling and is an established target for the treatment of
multiple subtypes of B-cell lymphomas and autoimmune disorders. (RC)